Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Adding checkpoint inhibitors to standard chemo didn't move the needle in MIBC. Both KEYNOTE-866 (pembrolizumab) and ENERGIZE (nivolumab) failed to significantly improve survival outcomes when layered onto cisplatin-based chemotherapy in muscle-invasive bladder cancer. The results point away from chemo-plus-checkpoint combinations — while enfortumab vedotin plus pembrolizumab steps up as the emerging standard of care.
Two long-awaited phase 3 trials presented at the 2026 ESMO Congress delivered a clear message: adding PD-1 checkpoint inhibitors to standard cisplatin-based chemotherapy doesn't significantly improve outcomes for patients with muscle-invasive bladder cancer (MIBC). In KEYNOTE-866, perioperative pembrolizumab plus neoadjuvant cisplatin and gemcitabine failed to meet its primary event-free survival (EFS) endpoint vs. placebo plus chemo. Similarly, the ENERGIZE trial found that perioperative nivolumab added to gemcitabine and cisplatin missed both co-primary endpoints — pCR rate and EFS.
Both trials showed numerically higher pathologic complete response (pCR) rates with immunotherapy, but neither reached statistical significance. Overall survival was also similar across arms in both studies. Safety profiles were consistent with known toxicities, though immune-related adverse events were more frequent in the immunotherapy arms.
By the Numbers
Why it matters: These back-to-back trial results clarify that chemo-plus-checkpoint isn't the path forward for cisplatin-eligible MIBC. The investigators of both trials concluded that the data do not support adding perioperative pembrolizumab or nivolumab to neoadjuvant cisplatin-based chemotherapy — with enfortumab vedotin plus pembrolizumab now FDA-approved and emerging as the new standard of care in this setting.
